Article Text
Statistics from Altmetric.com
Case presentation
A 29-year-old man presented to the emergency department after a motor vehicle collision, with aphasia, perseveration and no memory of the events leading up to the crash. His serum lactate was elevated, plasma glucose was normal, and urine toxicology was negative. CT scans of the head and neck were normal. He was thought to have had a first-time seizure and was discharged with a neurology follow-up.
One week later, he had an episode of aphasia and headache, progressing to a focal-to-bilateral tonic-clonic seizure, which resolved with lorazepam. There were no clear risk factors for epilepsy, and there was no personal or family history of seizures. On examination, he had fluctuating aphasia, right-sided neglect, right-hand apraxia, finger agnosia, acalculia and right-left confusion. An MR scan of the brain without contrast 6 days after symptom onset was normal (figure 1A). He was started on levetiracetam before discharge home.
Questions for consideration
How would you localise his transient neurological deficits?
Examination identified a tetrad of agraphia, acalculia, right-left disorientation and finger agnosia.1 This syndrome, often referred to as Gerstmann syndrome, usually localises to the dominant parietal lobe. The transient and recurrent nature of his symptoms suggested focal seizures as the underlying cause.1
Three …
Footnotes
AA and EFM are joint first authors.
X @albertaboseif
AA and EFM contributed equally.
Contributors JRA, AA and EFM: drafting, revision of the manuscript for content, including medical writing for content, major role in acquisition of data, study concept for design, analysis or interpretation of data. AK, VP and FHS: interpreted the data and revised the manuscript for intellectual content.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests JRA served on scientific advisory boards for of EMD Serono, Genentech, Horizon Therapeutics & TG Therapeutics; has received research support from Horizon Therapeutics. AK discloses personal compensation for consulting for Genentech, Horizon therapeutics, Alexion and EMD Serono. The remaining authors have no relevant disclosures.
Provenance and peer review Not commissioned. Externally peer reviewed by Emma Tallantyre, Cardiff, UK.